[go: up one dir, main page]

WO2006058867A3 - Substituierte pteridine zur behandlung von entzündlichen erkrankungen - Google Patents

Substituierte pteridine zur behandlung von entzündlichen erkrankungen Download PDF

Info

Publication number
WO2006058867A3
WO2006058867A3 PCT/EP2005/056244 EP2005056244W WO2006058867A3 WO 2006058867 A3 WO2006058867 A3 WO 2006058867A3 EP 2005056244 W EP2005056244 W EP 2005056244W WO 2006058867 A3 WO2006058867 A3 WO 2006058867A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
inflammatory diseases
diseases
substituted pteridines
pteridines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/056244
Other languages
English (en)
French (fr)
Other versions
WO2006058867A2 (de
Inventor
Domnic Martyres
Horst Dollinger
Peter Nickolaus
Birgit Jung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35697133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2006058867(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim International GmbH
Priority to CA002587261A priority Critical patent/CA2587261A1/en
Priority to EP05810977A priority patent/EP1819707A2/de
Priority to JP2007541993A priority patent/JP2008521772A/ja
Publication of WO2006058867A2 publication Critical patent/WO2006058867A2/de
Publication of WO2006058867A3 publication Critical patent/WO2006058867A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Die Erfindung betrifft neue Pteridine, die geeignet sind zur Behandlung von Atemwegs- oder gastrointestinalen Beschwerden oder Erkrankungen, entzündlichen Erkrankungen der Gelenke, der Haut oder der Augen, Erkrankungen des periphären oder zentralen Nervensystems oder Krebserkrankungen, sowie pharmazeutische Zusammensetzungen die diese Verbindungen beinhalten.
PCT/EP2005/056244 2004-11-29 2005-11-25 Substituierte pteridine zur behandlung von entzündlichen erkrankungen Ceased WO2006058867A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002587261A CA2587261A1 (en) 2004-11-29 2005-11-25 Substituted pteridines for the treatment of inflammatory diseases
EP05810977A EP1819707A2 (de) 2004-11-29 2005-11-25 Substituierte pteridine zur behandlung von entz]ndlichen erkrankungen
JP2007541993A JP2008521772A (ja) 2004-11-29 2005-11-25 炎症性疾患治療用の置換プテリジン

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004057645.9 2004-11-29
DE102004057645A DE102004057645A1 (de) 2004-11-29 2004-11-29 Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen

Publications (2)

Publication Number Publication Date
WO2006058867A2 WO2006058867A2 (de) 2006-06-08
WO2006058867A3 true WO2006058867A3 (de) 2006-10-26

Family

ID=35697133

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/056244 Ceased WO2006058867A2 (de) 2004-11-29 2005-11-25 Substituierte pteridine zur behandlung von entzündlichen erkrankungen

Country Status (6)

Country Link
US (1) US7718654B2 (de)
EP (1) EP1819707A2 (de)
JP (1) JP2008521772A (de)
CA (1) CA2587261A1 (de)
DE (1) DE102004057645A1 (de)
WO (1) WO2006058867A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004057595A1 (de) 2004-11-29 2006-06-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen
DE102004057618A1 (de) * 2004-11-29 2006-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen
DE102004057594A1 (de) * 2004-11-29 2006-06-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substitueirte Pteridine zur Behandlung von entzündlichen Erkrankungen
WO2007135027A1 (de) * 2006-05-24 2007-11-29 Boehringer Ingelheim International Gmbh Substituierte pteridine, die mit einem viergliedrigen heterocyclus substituiert sind
JP5440934B2 (ja) * 2006-05-24 2014-03-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換プテリジン
US20090318456A1 (en) * 2006-07-06 2009-12-24 Gilead Sciences, Inc. Substituted pteridines for the treatment and prevention of viral infections
WO2008009078A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
US10144736B2 (en) 2006-07-20 2018-12-04 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
WO2010016846A1 (en) * 2008-08-08 2010-02-11 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
EP3183251A4 (de) * 2014-08-22 2017-12-27 Janus Biotherapeutics, Inc. Neuartige n2,n4,n7,6-tetrasubstituerte pteridin-2,4,7-triamin- und 2,4,6,7-ted pteridin-verbindungen und verfahren zur synthese und verwendung davon
HUE038059T2 (hu) 2015-03-04 2018-10-29 Gilead Sciences Inc Toll-like receptor moduláló 4,6-diamino-pirido[3,2-D]pirimidin vegyületek
US10370342B2 (en) 2016-09-02 2019-08-06 Gilead Sciences, Inc. Toll like receptor modulator compounds
ES2826748T3 (es) 2016-09-02 2021-05-19 Gilead Sciences Inc Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
FI3700529T3 (fi) 2017-10-23 2025-09-18 Boehringer Ingelheim Int Uusi aktiivisten aineiden yhdistelmä etenevien fibrotisoivien interstitiaalisten keuhkosairauksien (pf-ild) hoitoon
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI879779B (zh) 2019-06-28 2025-04-11 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
AU2022404695B2 (en) 2021-12-09 2025-08-28 Boehringer Ingelheim International Gmbh New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
DK4426307T3 (da) 2021-12-09 2025-09-15 Boehringer Ingelheim Int Ny oral farmaceutisk sammensætning og doseringsplan til behandling af progressive fibroserende interstitielle lungesygdomme
EP4593838A1 (de) 2022-09-28 2025-08-06 Boehringer Ingelheim International GmbH Verwendung von biomarkern bei der behandlung von fibrotischen erkrankungen mit einem pde4b-hemmer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2940972A (en) * 1957-06-27 1960-06-14 Thomae Gmbh Dr K Tri-and tetra-substituted pteridine derivatives
EP0134922A1 (de) * 1983-07-02 1985-03-27 Dr. Karl Thomae GmbH Neue 2-Piperazino-pteridine, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE3445298A1 (de) * 1984-12-12 1986-06-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue pteridine, verfahren zu ihrer herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
DE3540952A1 (de) * 1985-11-19 1987-05-21 Thomae Gmbh Dr K Neue 2-piperazino-pteridine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
WO2003062240A1 (de) * 2002-01-23 2003-07-31 Faustus Forschungs Cie. Translational Cancer Research Gmbh Pteridinderivate, verfahren zu deren herstellung und ihre verwendung

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560685A (en) * 1984-06-18 1985-12-24 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung 2-Piperazino-pteridines useful as antithrombotics and antimetastatics
US7276506B2 (en) * 1998-12-28 2007-10-02 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
ATE277929T1 (de) * 1998-12-28 2004-10-15 4 Aza Bioscience Nv Immunsuppressive wirkungen von pteridinderivaten
GB0101577D0 (en) * 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
DE102004057595A1 (de) * 2004-11-29 2006-06-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen
DE102004057594A1 (de) * 2004-11-29 2006-06-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substitueirte Pteridine zur Behandlung von entzündlichen Erkrankungen
DE102004057618A1 (de) * 2004-11-29 2006-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2940972A (en) * 1957-06-27 1960-06-14 Thomae Gmbh Dr K Tri-and tetra-substituted pteridine derivatives
EP0134922A1 (de) * 1983-07-02 1985-03-27 Dr. Karl Thomae GmbH Neue 2-Piperazino-pteridine, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE3445298A1 (de) * 1984-12-12 1986-06-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue pteridine, verfahren zu ihrer herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
DE3540952A1 (de) * 1985-11-19 1987-05-21 Thomae Gmbh Dr K Neue 2-piperazino-pteridine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
WO2003062240A1 (de) * 2002-01-23 2003-07-31 Faustus Forschungs Cie. Translational Cancer Research Gmbh Pteridinderivate, verfahren zu deren herstellung und ihre verwendung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MERZ KARL-HEINZ ET AL: "Synthesis of 7-benzylamino-6-chloro-2-piperazino-4-pyrrolidinopterid ine and novel derivatives free of positional isomers. Potent inhibitors of cAMP-specific phosphodiesterase and of malignant tumor cell growth", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 41, no. 24, 19 November 1998 (1998-11-19), pages 4733 - 4743, XP002313878, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
DE102004057645A1 (de) 2006-06-01
CA2587261A1 (en) 2006-06-08
US7718654B2 (en) 2010-05-18
WO2006058867A2 (de) 2006-06-08
EP1819707A2 (de) 2007-08-22
JP2008521772A (ja) 2008-06-26
US20060116371A1 (en) 2006-06-01

Similar Documents

Publication Publication Date Title
WO2006058868A3 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
WO2007135026A3 (de) Substituierte pteridine als therapeutika
WO2006058867A3 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
WO2006113864A3 (en) Oxindole compounds and their uses as therapeutic agents
WO2006025991A3 (en) Isoindoline compounds and methods of making and using the same
ATE549338T1 (de) Substituierte pteridine, die mit einem viergliedrigen heterocyclus substituiert sind
WO2005070891A3 (en) Compounds and methods of use
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
EP2213684A3 (de) Nogo-A-Antikörper für die Behandlung von Alzheimer-Krankheit
WO2009050242A3 (de) Heterocyclus-substituierte piperazino-dihydrothienopyrimidine
WO2010048332A3 (en) Compounds for treating ophthalmic diseases and disorders
WO2006124748A3 (en) Multicyclic compounds and methods of their use
WO2006058869A3 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
EP2305640A3 (de) Substituierte Diphenyl-Ether, -Amine, -Sulfide und -Methane zur Behandlung von Beschwerden der Atemwege
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
WO2007002884A3 (en) 4-fluoro-piperidine t-type calcium channel antagonists
TW200611695A (en) Pyrrolopyridine derivatives
WO2007002361A3 (en) 3-fluoro-piperidine t-type calcium channel antagonists
WO2006056607A8 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
WO2008112840A3 (en) Novel composition and methods for the treatment of immune related diseases
MY142036A (en) New quaternized quinuclidine esters
TW200628473A (en) Novel heterocycles
WO2005092062A3 (en) Compounds for neurodegenerative disorders
WO2006135694A3 (en) Uii-modulating compounds and their use
WO2004021992A3 (en) Delivery of therapeutics to the brain and spinal cord

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2587261

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005810977

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007541993

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2005810977

Country of ref document: EP